PRESS RELEASE - July 12, 2007
CAVIT SCIENCES, INC. ANNOUNCES FILING OF CONTINUATIONS-IN-PART
Contact: Colm King
561-544 6988
info@cavitsciences.com
www.CavitSciences.com
Delray Beach, FL, July 12, 2007—Cavit Sciences, Inc. (“Cavit”) (OTCBB: CVIT) today announced the filing of continuations-in-part for both the Company’s Cancer Treatment and Viral Infection Treatment patent applications.
Cavit has recently completed the filing of continuations-in-part with the United States Patent and Trademark Office (“USPTO”) relating to the following two patent applications: 1) Methods and Compositions for Treatment of Cancer and 2) Methods and Compositions for Treatment of Viral Infections. As a result of ongoing research by Cavit’s team and outside scientists and researchers, Cavit has augmented its rights with additional compounds and additional indications.
In addition to the previous compounds of Tubercin, SSM and derivatives thereof, Cavit has added 19 compounds to both of our applications, due to their proven results in treating cancers, viral infections and related diseases. The compounds may be used alone or in combination therapy. The compounds may be homeopathic and/or holistic preparations and act as immunomodulators, which increase the efficiency of the immune system.
Based on the testing results of the above compounds, numerous additional indications have been added to both of our applications. These indications include the treatment of bacterial diseases, opportunistic infections and radiation therapy induced leukopenia. Also included are avian influenza (bird flu), MRSA, SIRS, SARS, BSE (sometimes referred to as “mad cow disease”) and various Staph infections.
We will continue to add to our intellectual property rights as we aggressively advance treatments in a rapid and cost-effective manner. We are working towards the goal of having treatments available to patients and individuals for the prevention and treatment of diseases in the U.S. and worldwide.
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. Cavit’s drugs have not been evaluated by the Food and Drug Administration and the efficacy of these drugs has not been confirmed by FDA-approved research. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, (ii) the ability of Cavit to finalize its manufacturing and distribution facilities, and (iii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit’s filings with the Securities and Exchange Commission, including those factors discussed under the caption \"Risk Factors\" for Cavit on Form 10K-SB filed on April 12, 2007.avit’s filings with the Securities and Exchange Commission, including those factors discussed under the caption \"Risk Factors\" for Cavit on Form 10K-SB filed on April 12, 2007.
For additional information about this udpate, please visit www.CavitSciences.com.
About Cavit Sciences - Cavit Sciences, Inc. (“Cavit”) is a biotechnology company that has three developed supplement lines with products that enhance, improve, maintain and support the body by beneficially affecting various conditions and is engaged in developing treatments and prevention for cancer, viral infections, opportunistic infections, related diseases and the immune system. New product information and updates will continue to be added to Cavit’s website.
- END -
© 2007 Cavit Sciences
